MDT-637: Phase I data

The double-blind, placebo-controlled, U.S. Phase I Study MDT-637-CP-103 trial in 10 patients with mild to moderate persistent asthma showed that single ascending-doses of MDT-637 up to 132 µg thrice daily were well tolerated with no significant adverse events or clinically significant changes in lung function reported. No cohorts of patients receiving MDT-637 reported treatment-related trends in clinical laboratory results, vital signs, ECG results or physical examination findings. Data were presented at the International Respiratory Syncytial Virus Symposium in Santa Fe. ...